(Q34623662)

English

Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naïve Asian patients with chronic hepatitis B: a meta-analysis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 August 2017

3 references

27 October 2020

8 April 2021

25 October 2022

0 references

Comparison of the 48-week efficacy between entecavir and adefovir in HBeAg-positive nucleos(t)ide-naïve Asian patients with chronic hepatitis B: a meta-analysis (English)

1 reference

Europe PubMed Central

3 August 2017

chronic hepatitis B

1 reference

22 June 2019

heterocyclic compound

1 reference

17 September 2019

organophosphonate

2 references

12 November 2019

8 April 2021

antiviral agent

1 reference

27 October 2020

1 reference

based on heuristic

inferred from title

author name string

Pan Zhao

1

1 reference

Europe PubMed Central

3 August 2017

Weiwei Liu

2

1 reference

Europe PubMed Central

3 August 2017

Jun Zhao

3

1 reference

Europe PubMed Central

3 August 2017

Qun Guan

4

1 reference

Europe PubMed Central

3 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

22 February 2011

9 references

Europe PubMed Central

3 August 2017

23 March 2019

21 March 2019

22 June 2019

17 September 2019

12 November 2019

27 October 2020

8 April 2021

25 October 2022

Virology Journal

9 references

Europe PubMed Central

3 August 2017

23 March 2019

21 March 2019

22 June 2019

17 September 2019

12 November 2019

27 October 2020

8 April 2021

25 October 2022

8

1 reference

Europe PubMed Central

3 August 2017

75

1 reference

Europe PubMed Central

3 August 2017

copyright license

Creative Commons Attribution 2.0 Generic

8 references

Europe PubMed Central

23 March 2019

Europe PubMed Central

21 March 2019

Europe PubMed Central

22 June 2019

Europe PubMed Central

17 September 2019

Europe PubMed Central

12 November 2019

Europe PubMed Central

27 October 2020

Europe PubMed Central

8 April 2021

Europe PubMed Central

25 October 2022

copyright status

0 references

on focus list of Wikimedia project

0 references

Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048568

7 July 2018

Clinical relevance and public health significance of hepatitis B virus genomic variations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048568

7 July 2018

Does RNA interference provide new hope for control of chronic hepatitis B infection?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048568

7 July 2018

Hepatitis B virus resistance to nucleos(t)ide analogues.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048568

7 July 2018

Efficacy and safety of entecavir compared to lamivudine in nucleoside-naïve patients with chronic hepatitis B: a randomized double-blind trial in China

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048568

7 July 2018

Side effects of long-term oral antiviral therapy for hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048568

7 July 2018

Endpoints of therapy in chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048568

7 July 2018

Benefits and risks of nucleoside analog therapy for hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048568

7 July 2018

Antiviral resistance and hepatitis B therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048568

7 July 2018

Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048568

7 July 2018

The oncogenic potential of hepatitis B virus rtA181T/ surface truncation mutant.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048568

7 July 2018

Therapeutic strategies in the management of patients with chronic hepatitis B virus infection.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048568

7 July 2018

Antiviral therapy of chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048568

7 July 2018

Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1186%2F1743-422X-8-75

21 January 2018

Efficacy and durability of generic adefovir dipivoxil in patients with HBeAg positive chronic hepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048568

26 October 2018

Novel mutation in YMDD motif and direct neighbourhood in a child with chronic HBV-infection and clinical lamivudine and adefovir resistance - a scholarly case

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048568

26 October 2018

Comparison of efficacy between adefovir dipivoxil and entecavir in patients with chronic hepatitis B

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048568

26 October 2018

HBV DNA level as an important determinant of E antigen seroconversion of chronic hepatitis B during adefovir dipivoxil therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048568

26 October 2018

Resistance to adefovir: a new challenge in the treatment of chronic hepatitis B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3048568

26 October 2018

Identifiers

10.1186/1743-422X-8-75

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

1 reference

Europe PubMed Central

3 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34623662&oldid=1758109393"